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Interactions with the human breast cancer resistance protein (hBCRP) significantly 36 
influence the pharmacokinetic properties of a drug and can even lead to drug-drug 37 
interactions. As efflux pump from the ABC superfamily, hBCRP utilized energy 38 
gained by adenosine 5'-triphosphate (ATP) hydrolysis for the transmembrane 39 
movement of its substrates, while adenosine 5'-diphosphate (ADP) and inorganic 40 
phosphate were released. The ADP liberation can be used to detect interactions with 41 
the hBCRP ATPase. An ADP quantification method based on hydrophilic interaction 42 
liquid chromatography (HILIC) coupled to high resolution tandem mass spectrometry 43 
(HR-MS/MS) was developed and successfully validated in accordance to the criteria 44 
of the guideline on bioanalytical method validation by the European Medicines 45 
Agency. ATP and adenosine 5'-monophosphate were qualitatively included to 46 
prevent interferences. Furthermore, a setup consisting of six sample sets was 47 
evolved that allowed detection of hBCRP substrate or inhibitor properties of the test 48 
compound. The hBCRP substrate sulfasalazine and the hBCRP inhibitor 49 
orthovanadate were used as controls. To prove the applicability of the procedure, the 50 
effect of amprenavir, indinavir, nelfinavir, ritonavir, and saquinavir on the hBCRP 51 
ATPase activity was tested. Nelfinavir, ritonavir, and saquinavir were identified as 52 
hBCRP ATPase inhibitors and none of the five HIV protease inhibitors turned out to 53 
be an hBCRP substrate. These findings were in line with a pervious publication. 54 
 55 
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1. Introduction 59 
Membrane transporters such as the human breast cancer resistance protein 60 
(hBCRP, also known as ABCG2 or MXR) are gaining more and more attention not 61 
only during development, but also for better understanding of pharmacokinetics and 62 
drug interactions [1]. In 2010, the International Transporter Consortium (ITC) 63 
highlighted the importance of seven key membrane transporters in drug development 64 
because of their major influence on the pharmacokinetic, safety, and efficacy profiles 65 
of drugs [1]. In 2012, the European Medicines Agency (EMA) and Food and Drug 66 
Administration (FDA) included these transport proteins in their guidelines on the 67 
investigation of drug interactions [2, 3]. 68 
One of the transporters highlighted by the ITC is hBCRP, an adenosine 5'-69 
triphosphate (ATP)-dependent efflux pump from the ABC superfamily, closely related 70 
to P-glycoprotein [1]. hBCRP is not only highly expressed in several cancer cells, 71 
where it was initially discovered, but also in normal human tissues including the small 72 
intestine, liver, brain endothelium, and placenta. It plays therefore an important role in 73 
the absorption, elimination, and tissue distribution of drugs and other xenobiotics [4]. 74 
For the transmembrane movement of its substrates, hBCRP utilized energy gained 75 
by ATP hydrolysis, while adenosine 5'-diphosphate (ADP) and inorganic phosphate 76 
are released [5].  77 
Besides more complicated models such as cell-based assays, intact organs, or 78 
transporter-deficient animals, membrane-based systems were often used to identify 79 
hBCRP substrates or inhibitors. Substrate-dependent ATP hydrolysis has been 80 
measured to evaluate the interactions with some ABC transporters usually by 81 
colorimetric analysis of the inorganic phosphate release [1]. Unfortunately, this 82 
reaction can be disturbed by colored samples [6]. Another approach, the analysis of 83 
not consumed ATP, was measured by a bioluminescence reaction using luciferase 84 
[7]. This method is also known to be interference-prone, particularly due to substrate 85 
instability [8]. Furthermore, the linear range of the reaction is below the 86 
concentrations expected in the reaction mixtures and all incubated samples had to be 87 
diluted prior to analysis [7]. So far, only a few studies were published using LC-MS 88 
for quantification of ADP [9-12] but none of them were applicable for the direct 89 
measurement of ADP in in vitro hBCRP ATPase activity studies. 90 
Therefore, the aim of the present study was the development of such a method 91 
using hydrophilic-interaction liquid chromatography (HILIC) coupled to high resolution 92 
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tandem mass spectrometry (HR-MS/MS) for ADP quantification and detection of ATP 93 
and adenosine 5'-monophosphate (AMP). The workup and analysis should be 94 
validated in accordance to international guidelines for bioanalytical procedures [13]. 95 
Furthermore, the applicability of the developed setup should be demonstrated by 96 
determining the influence of five HIV protease inhibitors on the in vitro hBCRP 97 
ATPase activity, from which were already data available for comparison [14]. 98 
 99 
2. Materials and methods 100 
2.1. Chemicals and enzymes 101 
The baculovirus-infected insect cell microsomes (Supersomes) containing 102 
human complementary DNA-expressed BCRP (Arg482, 5 mg protein/mL) and wild-103 
type Supersomes without hBCRP (control membrane, 5 mg protein/mL) used as 104 
negative control were obtained from Corning (Amsterdam, The Netherlands). After 105 
delivery, Supersomes were thawed at 37 °C, aliquoted, snap-frozen in liquid nitrogen, 106 
and stored at -80 °C until use. 107 
AMP disodium salt, ADP sodium salt, ATP magnesium salt, guanosine 5'-108 
diphospate (GDP) sodium salt, uridine 5'-phosphate (UDP) sodium salt hydrate, 109 
sulfasalazine, sodium orthovanadate, amprenavir, indinavir, nelfinavir, ritonavir, 110 
saquinavir mesylate, ammonium acetate, MES hydrate, and Trizma base were 111 
obtained from Sigma-Aldrich (Taufkirchen, Germany), formic acid (MS grade) from 112 
Fluka (Neu-Ulm, Germany), acetonitrile, methanol (both LC-MS grade), and all other 113 
chemicals from VWR (Darmstadt, Germany). 114 
Stock solutions were prepared in bidistilled water for sodium orthovanadate (10 115 
mM), AMP, ADP, ATP, GDP, and UDP (20 mM, respectively) or in methanol for 116 
sulfasalazine (0.5 mg/mL), amprenavir, indinavir, nelfinavir, ritonavir, and saquinavir 117 
(1 mg/mL, respectively). Stock solutions were aliquoted and stored at -20 °C until 118 
use. 119 
2.2. HILIC-HR-MS/MS apparatus 120 
A Thermo Fisher Scientific (TF, Dreieich, Germany) Dionex UltiMate 3000 121 
Rapid Separation (RS) LC system with a quaternary UltiMate 3000 RS pump and an 122 
UltiMate 3000 RS autosampler was used and controlled by the TF Chromeleon 123 
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software version 6.80. It was coupled to a TF Q-Exactive Plus equipped with a 124 
heated electrospray ionization II source (HESI-II). The gradient elution was 125 
performed on a Macherey-Nagel (Düren, Germany) HILIC Nucleodur column (125 × 126 
3 mm, 3 m) using aqueous ammonium acetate (200 mM, eluent A) and acetonitrile 127 
containing 0.1% (v/v) formic acid (eluent B). The flow rate was set to 700 µL/min and 128 
an isocratic elution with a duration of 6 min using 65% eluent B was performed at 40 129 
°C column temperature, maintained by a Dionex UltiMate 3000 RS analytical column 130 
heater. The injection volume for all samples was 1 µL. HESI-II conditions were as 131 
already described before [15]: sheath gas, 60 arbitrary units (AU); auxiliary gas, 10 132 
AU; spray voltage, 4.00 kV; heater temperature, 320 °C; ion transfer capillary 133 
temperature, 320 °C; and S-lens RF level, 60.0. Mass calibration was done prior to 134 
anal sis according to the manufacturer s recommendations using external mass 135 
calibration. For evaluating the chromatographic separation, a full scan experiment 136 
was used with the following scan parameters: polarity, negative; in-source collision-137 
induced dissociation (CID), 0 eV; microscan, 1; resolution, 35,000; automatic gain 138 
control (AGC) target, 1e6; maximum injection time (IT), 120 ms; and acquisition 139 
range, 100-600 m/z. The final quantification was performed using a targeted single 140 
ion monitoring (t-SIM) and a subsequent data-dependent MS2 (dd-MS2) mode with an 141 
inclusion list containing the exact masses of negatively charged AMP (m/z 142 
346.0558), ADP (m/z 426.0221), and ATP (m/z 505.9885). The settings for the t-SIM 143 
mode were as follows: polarity, negative; in-source CID, 0 eV; microscan, 1; 144 
resolution, 35,000; AGC target, 5e4; maximum IT, 100 ms; and isolation window, 4 145 
m/z. The cycle time for the t-SIM was 2.3 Hz. The settings for the dd-MS2 mode were 146 
as follows: microscan, 1; resolution, 35,000; AGC target, 2e5; maximum IT, 100 ms; 147 
isolation window, 4 m/z; and dynamic exclusion, 4 s. Limited by the dynamic 148 
exclusion, the cycle time for the dd-MS2 was set to 0.25 Hz. Quantification was 149 
performed using t-SIM, while dd-MS2 was only used for identification. TF Xcalibur 150 
Qual Browser 2.2 software was used for data handling. The settings for automated 151 
peak integration were as follows: mass tolerance, 5 ppm; peak detection algorithm, 152 
ICIS; area noise factor, 5; and peak noise factor, 300. GraphPad Prism 5.00 153 
(GraphPad Software, San Diego, USA) was used for statistical evaluation. 154 
2.3. Method validation 155 
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The ADP quantification method was validated in accordance to the Guideline 156 
on bioanal tical method validation  published b  the EMA [13]. Briefly, the method 157 
was tested for selectivity (using ten blank samples containing 0.2 mg/mL control 158 
membrane with and without ATP, respectively), carry-over (using a blank sample 159 
without ATP following the high quality control, QC), lower limit of quantification 160 
(LLOQ, equal to the lowest calibration standard), within-run accuracy and precision 161 
(analyzed in a single run six samples per level at four concentration levels: LLOQ 162 
QC, low QC, medium QC, and high QC), between-run accuracy and precision 163 
(analyzed in three different runs on three different days six samples per level at four 164 
concentration levels: LLOQ QC, low QC, medium QC, and high QC), dilution integrity 165 
(analyzed five samples spiked above the calibration range and diluted by factor five 166 
with blank matrix), matrix effect (using six samples with matrix and six samples 167 
without matrix at two concentration levels: low QC and high QC), and stability of 168 
processed samples in the autosampler (analyzed immediately after preparation and 169 
again after 24 h in the autosampler, three samples per level at two concentration 170 
levels: low QC and high QC). The calibration consisted of six concentration points 171 
(given in Table 1) equally distributed over the entire range. The concentrations of 172 
LLOQ QC, low QC, medium QC, and high QC were as follows: 50, 125, 250, and 375 173 
µM. Calibration standards and QCs were prepared from different stock solutions that 174 
were serially diluted with bidistilled water to obtain the final concentrations. Control 175 
membrane, diluted to a final concentration of 0.2 mg/mL with 50 mM Tris-MES buffer 176 
(pH 6.8), was used for sample preparation. Unless otherwise stated, 4 mM ATP was 177 
also present in the samples, which were not incubated. The final volume was 30 µL. 178 
Finally, the samples were diluted with the same volume of acetonitrile, centrifuged for 179 
2 min at 10,000×g, the supernatant was transferred to an autosampler vial, and 180 
analyzed by HILIC-HR-MS/MS. For quantification, the mean ADP area was used 181 
calculated after running each sample twice.  182 
After completed validation, all analytical runs consisted of two blank samples, 183 
the calibration standards in duplicate, three levels of QC samples (low, medium, and 184 
high) in duplicate, and the study samples. All samples were analyzed twice and the 185 
mean ADP area minus mean ADP area in blank samples was used for quantification. 186 
All calculations were done using GraphPad Prism 5.00 software. 187 
2.4. Incubation conditions for detection of hBCRP ATPase activity  188 
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Reaction conditions were adapted from Sarkadi et al. [16] with the following 189 
modifications. All reactions were carried out in 500 µL reaction tubes. Sulfasalazine, 190 
a known hBCRP substrate [17], was diluted with bidistilled water and used at a final 191 
concentration of 10 µM to ascertain appropriate incubation conditions. To check the 192 
protein dependency of the ATPase activity, the content of hBCRP membrane was 193 
varied between 0.1 and 0.8 mg/mL. To check the time dependency of the ATPase 194 
activity, incubation duration was varied between 5 and 60 min. To check the ATP 195 
dependency of the ATPase activity, ATP content was varied between 0.25 and 4 196 
mM. All incubations were conducted in duplicate. 197 
Final incubation mixtures contained 0.2 mg/mL hBCRP membrane and 4 mM 198 
ATP, as well as an hBCRP substrate or a mixture of an hBCRP substrate and an 199 
hBCRP inhibitor. ATP and substrate/inhibitor were diluted with bidistilled water and 200 
hBCRP membrane with Tris-MES buffer prior to incubations. The reaction was 201 
started by addition of ATP and stopped after 10 min of incubation at 37 °C by 202 
addition of 30 µL of ice-cold acetonitrile. The mixture was centrifuged for 2 min at 203 
10,000×g, the supernatant transferred to an autosampler vial, and analyzed by 204 
HILIC-HR-MS/MS. 205 
Incubations with sulfasalazine and 400 µM sodium orthovanadate, an inhibitor 206 
of ABC efflux pumps such as hBCRP [17], were also conducted.  207 
2.5. Application for determination of interactions with HIV protease inhibitors 208 
To test the influence of amprenavir, indinavir, nelfinavir, ritonavir, and saquinavir 209 
on hBCRP ATPase activity, six different sample sets consisting of three samples 210 
each were used as shown in Fig. 1. Incubation conditions were the same as 211 
described above. Sample set one contained one of the test compounds, set two one 212 
of the test compounds and sulfasalazine, sets three and five only sulfasalazine, set 213 
four sulfasalazine and orthovanadate, and set six none of these substances. All 214 
reactions were started by addition of ATP and sample sets one to five contained 215 
hBCRP membrane, while sample set six contained control membrane. Reactions of 216 
sample sets one to four and six were stopped by addition of pure acetonitrile, while 217 
acetonitrile used for set five contained the test compounds in addition. The HIV 218 
protease inhibitors were diluted with bidistilled water prior to incubations and had a 219 
final concentration of 50 µM. The ADP formation in sets one to five minus ADP 220 
formation in set six was then compared to each other. For statistical analysis of data, 221 
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a one-way ANOVA followed by Dunnett's multiple comparison test with set three as 222 
reference group (significance level, P < 0.05, 95% confidence intervals) was used. 223 
 224 
3. Results and discussion 225 
3.1. Development of the method 226 
For ABC transporters such as hBCRP, the transport process is associated with 227 
ATP binding and hydrolysis to provide energy for substrate translocation [4]. In the 228 
presence of ATP and a substrate, the hBCRP ATPase is activated and ATP 229 
consumed, while ADP and inorganic phosphate are released. If membrane fragments 230 
expressing the investigated transporter are used measurement of the substrate 231 
translocation is not possible, but the ATPase activity can be used as marker for 232 
interactions with hBCRP. Colorimetric analysis of the inorganic phosphate may 233 
provide a simple and practical approach [1]. As ATP has to be present in excess to 234 
be not the limiting factor of the reaction, the quantification of remaining ATP after 235 
termination is another possibility [7]. However, as already mentioned, both methods 236 
have several limitations such as disturbance by colored samples and substrate 237 
instability [6, 8]. Thus, the current method used hBCRP membranes and targeted the 238 
quantification of ADP that was not used as marker for determination of ATPase 239 
activity before. Furthermore, none of the described methods used the high flexibility 240 
and sensitivity of HR-MS/MS. HILIC was shown to provide sufficient retention and 241 
separation of small and polar compounds [18, 19], but also of the highly polar 242 
adenosine nucleotides [12, 20]. However, the method by Dowood et al. was 243 
developed to quantify 3'-phosphoadenosine-5'-phosphosulfate, while ADP and ATP 244 
were only qualitatively included to prevent interferences [20]. Li et al. quantified ADP, 245 
ATP, and four other cofactors in E. coli cells [12], but the linear range for ADP was 246 
below the concentrations that were expected in incubations with hBCRP membranes. 247 
Furthermore, the procedure was not validated in accordance to international 248 
guidelines and solid phase extraction followed by an analytical run time of 37 min 249 
would be far too time-consuming to screen a high number of samples for interactions 250 
with the hBCRP ATPase activity [12]. 251 
Chemical structures and HR-MS/MS spectra of AMP, ADP, and ATP are given 252 
in Fig. 2. Except for AMP, the mass of the precursor ion could not be detected in the 253 
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HR-MS/MS spectrum but the substances could be differentiated thanks to specific 254 
fragments anyway. To ensure chromatographic separation, a mixture of the pure 255 
substance solutions was used containing AMP, ADP, and ATP in water:acetonitrile 256 
1:1 (v/v) at a concentration of 2 mM, each. After successful separation, two peaks 257 
appeared in the t-SIM chromatogram of ADP as shown in Fig. 3A and both were 258 
most likely identified to be ADP based on the dd-MS2 spectrum. If ADP was injected 259 
alone, only one peak @ 3.5 min was detected. As the second ADP peak @ 4.0 min 260 
appeared only in solutions containing also ATP or exclusively ATP, this was most 261 
probably due to in-source fragmentation of ATP to ADP. However, as both peaks 262 
were chromatographically separated, it was possible to only integrate the prior one 263 
and use its area for ADP quantification in all samples.  264 
To correct experimental variability, an internal standard structurally similar to 265 
ADP such as GDP should be added. Unfortunately, even changes in the ratio of the 266 
eluents and an increased run time did not lead to complete separation of the analytes 267 
and addition of GDP caused tailing of the ADP signal, probably as result of column 268 
saturation during co-elution. Therefore, UDP was tested as internal standard. 269 
Surprisingly, the UDP signal increased with an increasing amount of ADP in the 270 
sample for unclear reasons. As these two compounds with structural similarity to 271 
ADP did not provide any benefit, no internal standard was used instead and results 272 
were still sufficient but to correct fluctuations during analysis, all samples were run 273 
twice and the mean ADP area was used. 274 
3.2. Method validation 275 
The analytical procedure based on HILIC-HR-MS/MS in t-SIM mode with a 276 
subsequent dd-MS2 mode allowed detection and identification of AMP, ADP, and 277 
ATP. While AMP and ATP were only qualitatively included, the quantification of ADP 278 
was successfully validated in accordance to the criteria of an international guideline 279 
[13]. To avoid imprecision in ADP quantification by permanent MS2 recording, 280 
dynamic exclusion of 4 s was used, what allowed repeated MS2 recording of the 281 
same precursor ion only after 4 s had passed. Experimental variability during 282 
analysis was corrected by duplicate analysis of each sample and calculation of the 283 
mean ADP area. Mean coefficient of determination for calibration curves are given in 284 
Table 1. Curve was fitted using linear regression without weighting. 285 
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The LLOQ was set equal to the lowest calibration standard as the practically 286 
relevant concentration range were way above the real LOQ. The method was 287 
selective at LLOQ levels if no ATP was contained in the analyzed samples as shown 288 
in Fig. 3B. In presence of ATP, ADP was detectable (Fig. 3C). ADP was already 289 
contained in the ATP pure substance solution as well. Therefore, it could either be an 290 
impurity in the ATP pure substance, that is isolated from a microbial source by the 291 
manufacturer, or formed during ATP dissolving. ATP is known to be stable for 292 
months in aqueous solution stored at -15 °C and only for approximately one week at 293 
0 °C [21]. Therefore, it was necessary to use always a freshly thawed ATP aliquot 294 
and to prepare two blank samples with ATP and to subtract the ADP area detected in 295 
these samples from the ADP area detected in all following samples. No carry-over 296 
was observed. The LLOQ for ADP was defined as 50 µM, which is the lowest ADP 297 
concentration that can be quantified reliably. The mean within-run and between-run 298 
accuracies ranged from 3 to 14% and were within 20% of the nominal values for the 299 
LLOQ QC and within 15% for the low, medium, and high QC samples. The mean 300 
within-run and between-run precisions ranged from 3 to 7%. Precisions were within 301 
20% for the LLOQ QC and within 15% for the low, medium, and high QC samples. 302 
Accuracy and precision data are summarized in Table 2. To investigate the matrix 303 
effect, the ratio of the peak area in presence of matrix to the peak area in absence of 304 
matrix was used. Those matrix factors were 1.5 and 1.3 for low and high QC levels 305 
with coefficients of variation of 9% and 6%, respectively, and thus not greater than 306 
15%. Chromatograms of a LLOQ QC and a high QC can be found in Fig. 3D and 3E, 307 
respectively. Fig. 3C-E show also, that AMP was detectable in samples containing 308 
ADP and/or ATP, even if they were not fortified with AMP. This was most likely due to 309 
an impurity in the pure substances of ADP and/or ATP. Processed samples provided 310 
stability in the autosampler for at least 24 h, corresponding to the maximum duration 311 
of the analytical runs, as mean concentrations of low and high QC levels were within 312 
±15% of the nominal values. 313 
3.3. Detection of hBCRP ATPase activity 314 
The hBCRP substrate sulfasalazine was used to demonstrate the detectability 315 
of ADP formed in in vitro incubations by hBCRP ATPase activity. Incubation time and 316 
enzyme concentration were varied and final conditions set in the linear range of ADP 317 
formation. Further incubations were therefore conducted with 0.2 mg/mL hBCRP 318 
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membrane for 10 min. To avoid non-specific protein binding, the protein 319 
concentrations were chosen as low as analytically possible as recommended by 320 
Baranczewski et al. [22]. The dependency of the ATP concentration was also tested 321 
because ATP should not be the limiting factor of the reaction. The highest amount of 322 
ADP was formed with 4 mM ATP. The final incubation conditions were similar to the 323 
hBCRP membrane manufacturer's recommendations, but the protein concentration 324 
could be chosen lower than suggested, thanks to the high sensitivity of HR-MS/MS 325 
reducing the risk of non-specific protein binding, as well as material costs. 326 
As ADP was also detected in incubations without sulfasalazine, the basal 327 
ATPase activity was determined. Therefore, hBCRP membranes were incubated with 328 
the hBCRP inhibitor orthovanadate in presence of sulfasalazine. The amount of 329 
formed ADP was comparable to that formed in incubations with control membrane. 330 
Control membranes provided constant, reproducible ATP consumption that was 331 
independent of the presence of other substances, such as sulfasalazine or 332 
orthovanadate. Therefore, the amount of ADP formed in incubations with control 333 
membrane could be used as blank samples and subtracted from that formed in 334 
incubations with hBCRP membrane. 335 
3.4. Effect of HIV protease inhibitors on hBCRP ATPase activity 336 
The experimental setup with six different sample sets (Fig. 1) allowed 337 
identification of hBCRP ATPase activity activators as well as inhibitors. Therefore, set 338 
one was used as activator test set and set two as inhibitor test set. Set three 339 
provided the activator positive control, using a known hBCRP substrate leading to 340 
activation of the hBCRP ATPase activity, and set four the inhibitor positive control. 341 
The ADP formation in set three was set to 100% hBCRP ATPase activity and the 342 
ADP formation in set four was below 10%, suggesting almost complete hBCRP 343 
ATPase activity inhibition. Set five allowed exclusion of mass spectral ion 344 
suppression or enhancement effects on the ADP detection caused by the test 345 
compounds [23]. Those interfering samples were mandatory, as only the adenosine 346 
nucleotides were monitored by the analytical method and co-eluting analytes could 347 
lead to false positive (in case of ion suppression) or false negative (in case of ion 348 
enhancement) results. For the five HIV protease inhibitors, no analytical interferences 349 
could be detected. A one-way ANOVA followed by Dunnett's multiple comparison test 350 
was used to decide whether ADP formation in sets one, two, four, or five was 351 
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statistically significantly different from ADP formation in set three. Similar initial 352 
screening strategies were published by Dinger et al. and Wagmann et al. to identify 353 
CYP or MAO inhibitors, respectively [19, 24]. ATPase activity in sample sets one and 354 
two are given in Fig. 5. Out of five test compounds, none could activate the hBCRP 355 
ATPase in a way comparable to sulfasalazine. Furthermore, amprenavir and indinavir 356 
were shown to have no hBCRP ATPase activity inhibition potential, while nelfinavir, 357 
ritonavir, and saquinavir were identified as hBCRP ATPase activity inhibitors. These 358 
results are in line with findings of Gupta et al. who studied hBCRP substrate or 359 
inhibitor properties of those five HIV protease inhibitors with human embryonic kidney 360 
cells stably expressing hBCRP by measuring intracellular mitoxantrone fluorescence 361 
using flow cytometry [14]. 362 
 363 
4. Conclusion 364 
The presented method was the first using ADP quantification by HILIC-HR-365 
MS/MS to detect in vitro hBCRP ATPase activity. The workup and analysis were 366 
validated according to international guidelines. Due to its high sensitivity, only small 367 
amounts of hBCRP membrane were needed, thus, reducing the risk of non-specific 368 
protein binding as well as material costs. Sample preparation by protein precipitation 369 
was simple and fast and the analysis time of 6 min for one analytical run allowed high 370 
throughput. Nevertheless, some shortcomings should be considered. The used 371 
orbitrap-based mass spectrometer is rather expensive and therefore not available for 372 
everyone but the use of a triple quadrupole mass spectrometer might be an 373 
alternative. Furthermore, no internal standard could be recommended as all tested 374 
compounds turned out to be inappropriate but ADP quantification could still be 375 
successfully performed. 376 
The approach was successfully applied to study interactions between hBCRP 377 
and five HIV protease inhibitors. Nelfinavir, ritonavir, and saquinavir were identified 378 
as hBCRP ATPase activity inhibitors, while amprenavir and indinavir did not inhibit 379 
hBCRP ATPase activity. None of the five HIV protease inhibitors turned out to be an 380 
hBCRP substrate. These findings were in line with published data [14]. Therefore, 381 
this approach should be able to predict possible interactions between the hBCRP 382 
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Table 1 Calibrator concentrations for ADP quantification and mean coefficient of 389 
determination (R2, ± coefficient of variation, CV) 390 
 Calibrator mean R2 (±CV) 
 1 2 3 4 5 6  
ADP conc., µM 50 100 200 300 400 500 0.9849 (±0.5) 
 391 
 392 
Table 2 Validation results for ADP quantification method: within-run and between-run 393 
accuracy and precision  394 
 LLOQ QC low QC med QC high QC 
Within-run 
accuracy, % 9 6 3 14 
Between-run 
accuracy, % 7 8 10 10 
Within-run 
precision, % 4 3 3 3 
Between-run 
precision, % 4 7 4 3 
 395 
  396 
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Legends to the figures 397 
 398 
Fig. 1 Incubation scheme for detection of human breast cancer resistance protein 399 
(hBCRP) ATPase activity using six sample sets (ATP: adenosine 5'-triphosphate, 400 
ACN: acetonitrile). 401 
Fig. 2 Chemical structures and HR-MS/MS spectra of adenosine 5'-monophosphate 402 
(AMP), adenosine 5'-diphosphate (ADP), and adenosine 5'-triphosphate (ATP). 403 
Fig. 3 Targeted-SIM chromatograms of adenosine 5'-monophosphate (AMP), 404 
adenosine 5'-diphosphate (ADP), and adenosine 5'-triphosphate (ATP) in a mixture 405 
of pure sample solutions (2 mM, each; A), a blank sample (B), a blank sample spiked 406 
with 4 mM ATP (C), a LLOQ QC (50 µM ADP and 4 mM ATP; D), and a high QC 407 
(375 µM ADP and 4 mM ATP; E).  408 
Fig. 4 Overlaid targeted-SIM chromatograms of adenosine 5'-diphosphate (ADP) in 409 
incubated samples containing adenosine 5'-triphosphate (ATP, 4 mM), hBCRP 410 
membrane (0.2 mg/mL), and an hBCRP substrate (10 µM sulfasalazine; sample A), 411 
additionally an hBCRP inhibitor (400 µM orthovanadate; sample B) or ATP (4 mM) 412 
and control membrane (0.2 mg/mL; sample C). The peaks @ 3.56 min were used for 413 
ADP quantification, while peaks @ 4.03 min were most likely caused by in-source 414 
fragmentation of ATP.  415 
Fig. 5 Effect of 50 µM amprenavir, indinavir, nelfinavir, ritonavir, or saquinavir on 416 
hBCRP ATPase activity. Sample set one contained human breast cancer resistance 417 
protein (hBCRP) membrane, adenosine 5'-triphosphate (ATP), and one of the HIV 418 
protease inhibitors, while sample set two contained sulfasalazine in addition. 419 
Percentage of activity represented the percentage of adenosine 5'-diphosphate 420 
(ADP) formation in relation to hBCRP ATPase activator positive control incubations 421 
only with sulfasalazine (100%). Values are expressed as mean and were tested for 422 
significance (n = 3, ***, P < 0.001, **, P < 0.01, *. P < 0.1 for ADP formation in 423 
incubations with test compound versus ADP formation in activator positive control 424 
incubations). 425 
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